Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 106Thoracic 68Lymphoid 23Genitourinary 8Sarcoma 6Other solid neoplasm 6CNS 6Gynecologic 5Gastrointestinal 5Plasma cell 3Dermatologic 2Tumor-Agnostic 1Other hematologic neoplasm 1NET 1Head & Neck 1Endocrine 1

Conditions

Melanoma 2

Interventions

Nivolumab 114Ipilimumab 114pembrolizumab 108aldesleukin 76Cyclophosphamide 70fludarabine phosphate 51Interleukin-2 48Temozolomide 41Dacarbazine 36trametinib 33dabrafenib 30Bevacizumab 30sargramostim 29Radiotherapy 29incomplete Freund's adjuvant 27fludarabine 27Vemurafenib 25Radiosurgery 25Carboplatin 25Paclitaxel 23binimetinib 22Biopsy 22CTLA-4 Antigen 21Peripheral Blood Stem Cell Transplantation 20encorafenib 19cemiplimab 19atezolizumab 19Mycophenolic Acid 19HhAntag691 19Aminolevulinic Acid 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Vinorelbine × Dermatologic × Clear all
NCT00256282 2018-05-03

Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma

University of California, Irvine

Phase 2 Completed
52 enrolled 8 charts
Dermatologic

Melanoma

NCT00003828 2012-08-22

S9804: Vinorelbine in Treating Patients With Stage IV Melanoma

SWOG Cancer Research Network

Phase 2 Completed
24 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡